• Skip to main content
  • Skip to footer
651-641-2804info@uelmn.org
Request Info
  • Connect With Us
  • Reservations
  • Events

UEL | Saint Paul | University Enterprise Labs | Incubator | Start-Ups

  • Why UEL?
    • Equity and Inclusion
    • Benefits and Mission
    • UEL Companies
  • Facilities
    • Space at UEL
    • Amenities
    • COVID-19
  • Cool Stuff
    • Case Studies
    • Programming
    • Resources
    • Photo Gallery
  • Insights
  • About
    • UEL’s History
    • Board of Directors
    • UEL Team
    • UEL Success Stories
  • Partners
    • gBETA Affiliates
    • Partner Overview
    • Partnership Inquiry
    • UEL Companies
  • Connect With Us
  • Reservations
  • Events
  • Residents
  • BARDA DRIVe

Regenerative Medicine Startup Peytant Solutions, Inc. “Graduates” from UEL, Receives $100k Biobusiness Grant and Pursues Additional Funding

September 30, 2017

Peytant Solutions, Inc., headed by CEO John Schorgl, is committed to improving quality of life for patients worldwide by utilizing regenerative biomaterials to provide transformational solutions for luminal diseases.  The first product in the platform is the AMStent™ System. Intended for treatment of malignant airway strictures, the AMStent System covers stent technology with human amnion tissue. Unlike synthetic coverings, which elicit an immune reaction, amniotic tissue is a natural material that provides a scaffold to support attachment of native epithelial cells. Amniotic tissue has an extensive clinical history, is well-tolerated, and exhibits minimal immunogenicity. AMStent will provide end-of-life palliative relief for patients who need it most.

A new “home” with a clean room, and securing grant monies to conduct sterilization and biocompatibility validation testing, brings Peytant Solutions two big steps closer to 510k application submission.  “It was tough to leave the close-knit ‘garage’ environment at UEL,” said Schorgl.  “UEL provided a supportive launching pad, and we’ll always be grateful for the experience and opportunity they afforded us.” The sentiment flows both ways, “While we love to see our tenants outgrow our UEL innovation community, well-positioned for the next phase, it’s a little bittersweet to see Peytant go. We wish them great success,” said Lynne Osterman, UEL Executive Director.

Driving commercialization of a predicate device with novel technology in the $13.3B global stent market requires funding.  Peytant Solutions is currently raising $4M to support FDA clearance.  The company is off to a great start after being awarded a 2017 Biobusiness Grant from Regenerative Medicine Minnesota.    

Filed Under: News

Footer

  • Our Benefits and Mission
  • Space at UEL
  • Amenities
  • Resources
  • Partnerships
  • Upcoming Events
  • Latest News
  • Our Alumni

UEL is committed to the safety and well-being for all of our community.  Click here for our COVID-19 Preparedness Plan.

Click a logo to go to their webpage and more information on our associations


 

 



1000 Westgate Drive
Saint Paul, MN 55114
Map

651-641-2804

24-Hour Emergency

 

952-854-8800
info@uelmn.org

Keep in Touch

sign up for our monthly newsletter

Copyright © 2022 UEL MN | All Rights Reserved | Privacy Policy and Terms of Service | Minneapolis Web Design by BizzyWeb | Log in